Literature DB >> 26815885

Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study.

J Schmidt1, A Smail2, B Roche3, P Gay3, V Salle1, H Pellet, P Duhaut1.   

Abstract

OBJECTIVE: To assess the incidence of infections leading to hospitalization, the mortality rate related to infections, and the determinants of these factors in patients with giant cell arteritis (GCA).
METHODS: In total, 486 patients with GCA (75% women) were enrolled at the time of diagnosis. All patients fulfilled the American College of Rheumatology criteria for GCA. As controls, age- and sex-matched subjects were randomly selected from the general population and matched to patients at the time of diagnosis of GCA. Both groups were prospectively followed up over a 5-year period.
RESULTS: Severe infections were more frequent among patients with GCA during the first year after diagnosis, compared to general population controls (incidence rate ratio 2.1, 95% confidence interval [95% CI] 1.2-3.4; incidence rate 11.1/100 patient-years [95% CI 8.3-14.6] in patients with GCA versus 5.9/100 patient-years [95% CI 4-8.4] in controls). Specifically, septic shock and infectious colitis were more frequent among the patients with GCA. Mortality caused by infections was higher in patients with GCA compared to controls (P < 0.0001 by log rank test). In analyses adjusted for age, among patients with GCA, a diagnosis of diabetes (hazard ratio [HR] 3.3, 95% CI 1.4-7.7) and a corticosteroid dosage that was >10 mg/day after 12 months of treatment (HR 4.61, 95% CI 1.38-15.36) were associated with death attributed to severe infection. The observed overall incidence of mortality was increased in patients with GCA during the early period of enrollment in the study (before 1997) (P = 0.0001 by log rank test), but thereafter was the same as that in the general population controls.
CONCLUSION: Frequencies of severe infections and rates of infection-related mortality are increased during the first year after the diagnosis of GCA. The risk of infection increases in GCA patients with older age or in the presence of diabetes, or is greater when the dosage of corticosteroids has been increased to >10 mg/day after 12 months of treatment.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2016        PMID: 26815885     DOI: 10.1002/art.39596

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  16 in total

Review 1.  Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management.

Authors:  Alvise Berti; Roberto Caporali; Carlomaurizio Montecucco; Giuseppe Paolazzi; Sara Monti
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

Review 2.  [Glucocorticoids in the treatment of giant cell arteritis : How much, how long and how to spare?]

Authors:  Bernhard Hellmich
Journal:  Z Rheumatol       Date:  2021-03-12       Impact factor: 1.372

3.  Sarcoidosis Increases Risk of Hospitalized Infection. A Population-based Study, 1976-2013.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Eric L Matteson
Journal:  Ann Am Thorac Soc       Date:  2017-05

4.  Abdominal Pain in a Patient With Giant Cell Arteritis.

Authors:  Tharani Sundararajan; Krati Chauhan
Journal:  Cureus       Date:  2022-04-14

Review 5.  Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes.

Authors:  Efstathios Kastritis; George D Kitas; Dimitrios Vassilopoulos; Georgios Giannopoulos; Meletios A Dimopoulos; Petros P Sfikakis
Journal:  Rheumatol Int       Date:  2020-07-11       Impact factor: 2.631

6.  Cryptococcal Meningitis in A Patient With Giant Cell Arteritis.

Authors:  Jin Lv; Qiankun Zhang
Journal:  Arch Rheumatol       Date:  2017-04-04       Impact factor: 1.472

7.  Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.

Authors:  Hubert de Boysson; Maelle Le Besnerais; Félix Blaison; Aurélie Daumas; Pierre-André Jarrot; François Perrin; Nathalie Tieulié; Alexandre Maria; Pierre Duffau; Bruno Gombert; Maxime Samson; Olivier Espitia; Marc Lambert; Arsène Mékinian; Achille Aouba
Journal:  Arthritis Res Ther       Date:  2021-05-19       Impact factor: 5.156

Review 8.  Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update.

Authors:  Gideon Nesher; Gabriel S Breuer
Journal:  Rambam Maimonides Med J       Date:  2016-10-31

9.  Does low risk of infections as a marker of effective immunity predict increased risk of subsequent giant cell arteritis or polymyalgia rheumatica? A Danish population-based case-control study.

Authors:  Clément Brault; Anders H Riis; Anil Mor; Pierre Duhaut; Reimar W Thomsen
Journal:  Clin Epidemiol       Date:  2018-10-16       Impact factor: 4.790

Review 10.  Profile of tocilizumab and its potential in the treatment of giant cell arteritis.

Authors:  Susan Patricia Mollan; John Horsburgh; Bhaskar Dasgupta
Journal:  Eye Brain       Date:  2018-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.